Clinical Trial

Personalized Antisense Oligonucleotide Therapy for A Single Patient With CHCHD10 ALS (nL18576)

Name: Personalized Antisense Oligonucleotide Therapy for A Single Patient With CHCHD10 ALS (nL18576) — clinical trial record (NCT07423494)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 1/2

View on ClinicalTrials.gov →

Summary

This research project entails delivery of a personalized antisense oligonucleotide (ASO) drug designed for a single participant with amyotrophic lateral sclerosis (ALS) due to a pathogenic variant in CHCHD10

Trial Details

NCT Number	NCT07423494
Lead Sponsor	n-Lorem Foundation Collaborators: Mayo Clinic
Conditions	Amyotrophic Lateral Sclerosis
Enrollment	1 participants
Start Date	2026-03
Primary Completion	2027-03 (estimated)
Study Completion	2027-03 (estimated)
Updated on ClinicalTrials.gov	2026-02-20